Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06050733 · ClinicalTrials.gov registry record
The Gut Microbiome and Immunotherapy Response in Solid Cancers
A clinical trial of Cancer, sponsored by The University of Texas Medical Branch, Galveston.
- Recruiting
- Registry status
- 16
- Enrollment target
- 1
- Study location
NCT06050733: Recruiting study of Cancer, sponsored by The University of Texas Medical Branch, Galveston.
NCT06050733 is a study of Cancer that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 16 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06050733, a study of Cancer, is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.
- RECRUITING
- Registry status
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is characterize the gastrointestinal microbiomes of patient with solid cancer undergoing standard of care treatment with programmed cell death protein 1 (PD-1) /programmed cell death ligand (PD-L1) blockade.
Primary Outcome
Characterization of the fecal microbiome using a commercially available sampling kit and our lab's patented array for PCR.
Conditions Studied
Study Locations (1)
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-06-30 |
| Est. Completion | 2026-12-30 |
What NCT06050733 shows while recruiting
NCT06050733 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06050733 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06050733 about?
NCT06050733 is a clinical study titled "The Gut Microbiome and Immunotherapy Response in Solid Cancers". The aim of this study is characterize the gastrointestinal microbiomes of patient with solid cancer undergoing standard of care treatment with programmed cell death protein 1 (PD-1) /programmed cell death ligand (PD-L1) blockade.
What is the current status of trial NCT06050733?
This trial is currently recruiting. The enrollment target is 16 participants. The study started on 2023-06-30. Estimated completion is 2026-12-30.
What conditions does trial NCT06050733 study?
This clinical trial studies the following conditions: Cancer.
Who is sponsoring clinical trial NCT06050733?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06050733 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06050733's enrollment target sits among peer trials
16 581st of 615 higher than 32 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI